(Q81292766)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

11

David B Weiner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Shakuntala Megati

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Dorys Garcia-Hand

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Sarah Cappello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Vidia Roopchand

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Amjed Masood

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Rong Xu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Amara Luckay

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Siew-Yen Chong

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Margherita Rosati

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Solomon Sackitey

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Barbara K Felber

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

George N Pavlakis

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Zimra R Israel

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Larry R Smith

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

John H Eldridge

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Maninder K Sidhu

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Michael A Egan

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

24 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

5083-5094

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

Direct gene transfer into mouse muscle in vivo

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Immunization of animals: from DNA to the dinner plate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Epidermal DNA vaccine for influenza is immunogenic in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Rational design of gene-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Structural and functional analysis of the RNA transport element, a member of an extensive family present in the mouse genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Fasciola hepatica: humoral and cytokine responses to a member of the saposin-like protein family following delivery as a DNA vaccine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Cellular protein is the source of cross-priming antigen in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II co

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Comparison of HPV DNA vaccines employing intracellular targeting strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

In vivo antigen stability affects DNA vaccine immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

beta-catenin is a target for the ubiquitin-proteasome pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

DNA immunization of mice against SIVmac239 Gag and Env using Rev-independent expression plasmids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

CD8+ T cell cross-priming via transfer of proteasome substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Antigen bias in T cell cross-priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

7 January 2021

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

7 January 2021

DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

7 January 2021

The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.092

7 January 2021

Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.

1 reference

12 December 2020

In vivo priming by DNA injection occurs predominantly by antigen transfer.

1 reference

12 December 2020

Purification and characterization of a kanamycin nucleotidyltransferase from plasmid pUB110-carrying cells of Bacillus subtilis

1 reference

12 December 2020

DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60).

1 reference

12 December 2020

Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.

1 reference

12 December 2020

TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide

1 reference

12 December 2020

Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes.

1 reference

12 December 2020

Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein

1 reference

12 December 2020

Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes

1 reference

12 December 2020

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment

1 reference

12 December 2020

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

1 reference

12 December 2020

Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B

1 reference

12 December 2020

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

1 reference

12 December 2020

Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation

1 reference

12 December 2020

10.1016/J.VACCINE.2008.03.092

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18485543%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference